Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial

What Was Tested

Researchers studied Liraglutide in the context of psoriasis and psoriatic arthritis in this randomized controlled trial publication.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

A total of 20 obese (body mass index > 25 kg/m(2)), glucose-tolerant patients with plaque psoriasis (psoriasis area and severity index (PASI) of at least 8) were randomized 1:1 to once-daily subcutaneous injections with liraglutide or placebo for an 8-week period.

How the Study Was Run

The researchers set it up as a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Secondary end points included changes in weight and high sensitive C-reactive protein (hsCRP) levels, as well as adverse events.

What Was Measured

PubMed files the paper under topics including Adalimumab, Anti-Inflammatory Agents, Glucose Tolerance Test, Liraglutide, Psoriasis, Registries and Glucagon-Like Peptide-1 Receptor Agonists.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Liraglutide in people with psoriasis and psoriatic arthritis.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Journal of the European Academy of Dermatology and Venereology : JEADV), a journal based in England.

More context: the Liraglutide compound page, Psoriasis and psoriatic arthritis research.